TY - JOUR
T1 - Expanded phenotype of AARS1-related white matter disease
AU - Helman, Guy
AU - Mendes, Marisa I.
AU - Nicita, Francesco
AU - Darbelli, Lama
AU - Sherbini, Omar
AU - Moore, Travis
AU - Derksen, Alexa
AU - Amy Pizzino, Pizzino
AU - Carrozzo, Rosalba
AU - Torraco, Alessandra
AU - Catteruccia, Michela
AU - Aiello, Chiara
AU - Goffrini, Paola
AU - Figuccia, Sonia
AU - Smith, Desiree E.C.
AU - Hadzsiev, Kinga
AU - Hahn, Andreas
AU - Biskup, Saskia
AU - Brösse, Ines
AU - Kotzaeridou, Urania
AU - Gauck, Darja
AU - Grebe, Theresa A.
AU - Elmslie, Frances
AU - Stals, Karen
AU - Gupta, Rajat
AU - Bertini, Enrico
AU - Thiffault, Isabelle
AU - Taft, Ryan J.
AU - Schiffmann, Raphael
AU - Brandl, Ulrich
AU - Haack, Tobias B.
AU - Salomons, Gajja S.
AU - Simons, Cas
AU - Bernard, Geneviève
AU - van der Knaap, Marjo S.
AU - Vanderver, Adeline
AU - Husain, Ralf A.
N1 - Funding Information: We thank the patients and their families. G.H. was supported by the Ochsner MD-PhD scholarship and a MCRI PhD Top-Up Scholarship. The participation of G.H. and C.S. is in part financed by the Australian National Health and Medical Research Council (NHMRC 1068278). The research conducted at the Murdoch Children’s Research Institute was supported by the Victorian Government’s Operational Infrastructure Support Program. This work was supported by the Italian Ministry of Health, grant RF-2016-02361241 (to E.B. and P.G.). T.B.H. was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)–Projektnummer (418081722). This study was partly supported by a grant from the Canadian Institutes of Health Research to G.B. (CIHR; 201610PJT-377869). G.B. has received the CIHR New Investigator Salary Award (2017-2022). Publisher Copyright: © 2021, The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics.
PY - 2021/12
Y1 - 2021/12
N2 - Purpose: Recent reports of individuals with cytoplasmic transfer RNA (tRNA) synthetase-related disorders have identified cases with phenotypic variability from the index presentations. We sought to assess phenotypic variability in individuals with AARS1-related disease. Methods: A cross-sectional survey was performed on individuals with biallelic variants in AARS1. Clinical data, neuroimaging, and genetic testing results were reviewed. Alanyl tRNA synthetase (AlaRS) activity was measured in available fibroblasts. Results: We identified 11 affected individuals. Two phenotypic presentations emerged, one with early infantile–onset disease resembling the index cases of AARS1-related epileptic encephalopathy with deficient myelination (n = 7). The second (n = 4) was a later-onset disorder, where disease onset occurred after the first year of life and was characterized on neuroimaging by a progressive posterior predominant leukoencephalopathy evolving to include the frontal white matter. AlaRS activity was significantly reduced in five affected individuals with both early infantile–onset and late-onset phenotypes. Conclusion: We suggest that variants in AARS1 result in a broader clinical spectrum than previously appreciated. The predominant form results in early infantile–onset disease with epileptic encephalopathy and deficient myelination. However, a subgroup of affected individuals manifests with late-onset disease and similarly rapid progressive clinical decline. Longitudinal imaging and clinical follow-up will be valuable in understanding factors affecting disease progression and outcome.
AB - Purpose: Recent reports of individuals with cytoplasmic transfer RNA (tRNA) synthetase-related disorders have identified cases with phenotypic variability from the index presentations. We sought to assess phenotypic variability in individuals with AARS1-related disease. Methods: A cross-sectional survey was performed on individuals with biallelic variants in AARS1. Clinical data, neuroimaging, and genetic testing results were reviewed. Alanyl tRNA synthetase (AlaRS) activity was measured in available fibroblasts. Results: We identified 11 affected individuals. Two phenotypic presentations emerged, one with early infantile–onset disease resembling the index cases of AARS1-related epileptic encephalopathy with deficient myelination (n = 7). The second (n = 4) was a later-onset disorder, where disease onset occurred after the first year of life and was characterized on neuroimaging by a progressive posterior predominant leukoencephalopathy evolving to include the frontal white matter. AlaRS activity was significantly reduced in five affected individuals with both early infantile–onset and late-onset phenotypes. Conclusion: We suggest that variants in AARS1 result in a broader clinical spectrum than previously appreciated. The predominant form results in early infantile–onset disease with epileptic encephalopathy and deficient myelination. However, a subgroup of affected individuals manifests with late-onset disease and similarly rapid progressive clinical decline. Longitudinal imaging and clinical follow-up will be valuable in understanding factors affecting disease progression and outcome.
UR - http://www.scopus.com/inward/record.url?scp=85113566436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113566436&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41436-021-01286-8
DO - https://doi.org/10.1038/s41436-021-01286-8
M3 - Article
C2 - 34446925
SN - 1098-3600
VL - 23
SP - 2352
EP - 2359
JO - Genetics in medicine
JF - Genetics in medicine
IS - 12
ER -